Your browser doesn't support javascript.
Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: A proposal for a multi-centric prospective trial.
Algara, M; Arenas, M; Marin, J; Vallverdu, I; Fernandez-Letón, P; Villar, J; Fabrer, G; Rubio, C; Montero, A.
  • Algara M; Department of Radiation Oncology, Hospital del Mar, Autonomous University of Barcelona, Spain.
  • Arenas M; Department of Radiation Oncology, University Hospital Sant Joan de Reus, Rovira iV irgili University, Tarragona, Spain.
  • Marin J; Intensive Care Unit, Hospital del Mar, Barcelona, Spain.
  • Vallverdu I; Intensive Care Unit University Hospital Sant Joan de Reus, Universitat Rovira I Virgili, Tarragona, Spain.
  • Fernandez-Letón P; Department of Radiation Physics, University Hospital HM Sanchinarro, Madrid, Spain.
  • Villar J; Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain.
  • Fabrer G; Department of Geriatric and Palliative Care, University Hospital Sant Joan de Reus, Rovira i Virgili University, Tarragona, Spain.
  • Rubio C; Department of Radiation Oncology, University Hospital HM Sanchinarro, Madrid, Spain.
  • Montero A; Department of Radiation Oncology, University Hospital HM Sanchinarro, Madrid, Spain.
Clin Transl Radiat Oncol ; 24: 29-33, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-598827
ABSTRACT

BACKGROUND:

COVID-19 is a highly contagious viral infection with high morbidity that is draining health resources. The biggest complication is pneumonia, which has a serious inflammatory component, with no standardized treatment. Low-dose radiation therapy (LD-RT) is non-invasive and has anti-inflammatory effects that can interfere with the inflammatory cascade, thus reducing the severity of associated cytokine release and might be useful in the treatment of respiratory complications caused by COVID-19. STUDY DESIGN AND

METHODS:

This multicentric prospective clinical trial seeks to evaluate the efficacy of bilateral lung LD-RT therapy as a treatment for interstitial pneumonia in patients with COVID-19 for improving respiratory function.This prospective study will have 2 phases I) an exploratory phase enrolling 10 patients, which will assess the feasibility and efficacy of low-dose lung irradiation, evaluated according to an increase in the PaO2/FiO2 ratio of at least 20% at 48-72 h with respect to the pre-irradiation value. If a minimum efficiency of 30% of the patients is not achieved, the study will not be continued. II) Non-randomized comparative phase in two groups a control group, which will only receive pharmacological treatment, and an experimental arm with pharmacological treatment and LD-RT. It will include 96 patients, the allocation will be 1 2, that is, 32 in the control arm and 64 in the experimental arm. The primary end-point will be the efficacy of LD-RT in patients with COVID-19 pneumonia according to an improvement in PaO2/FiO2. Secondary objectives will include the safety of bilateral lung LD-RT, an improvement in the radiology image, overall mortality rates at 15 and 30 days after irradiation and characterizing anti-inflammatory mechanisms of LD-RT by measuring the level of expression of adhesion molecules, anti-inflammatory cytokines and oxidative stress mediators.Trial registration ClinicalTrial.gov NCT-04380818 https//clinicaltrials.gov/ct2/show/NCT04380818?term=RADIOTHERAPY&cond=COVID&draw=2&rank=4.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: Clin Transl Radiat Oncol Year: 2020 Document Type: Article Affiliation country: J.ctro.2020.06.005

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: Clin Transl Radiat Oncol Year: 2020 Document Type: Article Affiliation country: J.ctro.2020.06.005